ISFIYA, Israel and BOSTON, Jan.10, 2018 /PRNewswire/
-- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ:
CHEK) (NASDAQ: CHEKW), a clinical-stage medical diagnostics
company engaged in the development of C-Scan®, an ingestible
capsule for preparation-free, colorectal cancer screening, today
announced it has received CE Mark approval for the C-Scan
system.
The C-Scan system offers an alternative to current colon cancer
screening methods that require laxative preparation and invasive
endoscopic procedures. This novel platform consists of a fully
autonomous system that utilizes an ingestible, ultra-low dose X-ray
capsule combined with a state of the art wireless tracking system,
enabling generation of structural information on the lumen of the
colon. This information is used to create 2D and 3D maps of the
colon, allowing physicians to identify pre-cancerous polyps and
other abnormalities. C-Scan is designed to improve the patient
experience and increase the number of adults screened by
eliminating procedural requirements frequently cited as barriers to
adherence to screening guidelines such as bowel preparation,
fasting, and sedation.
Bill Densel, CEO of Check-Cap
commented, "Achieving CE Mark approval is a significant
accomplishment and an important milestone for our Company.
This is a key validation of C-Scan and its potential as a
convenient and comfortable option for identifying polyps in the
colon. We look forward to continued progress on our initiatives and
remain on target to commence our European post-approval and U.S.
pilot trials, each in the 1H2018, as we define marketing and
commercialization pathways throughout 2018."
Colorectal cancer is the third most common cancer diagnosed in
both men and women and the second leading cause of cancer-related
deaths. Despite evidence showing the removal of adenomatous polyps
reduces CRC incidence and mortality, global screening rates remain
low, with approximately 1.4 million new cases of CRC diagnosed
world-wide each year, contributing to nearly 700,000 deaths.
About Check-Cap
Check-Cap is a clinical-stage medical diagnostics company
developing C-Scan®, the first capsule-based system for
preparation-free colorectal cancer screening.
Utilizing innovative ultra-low dose X-ray and wireless
communication technologies, the capsule generates information on
the contours of the inside of the colon as it passes naturally.
This information is used to create a 3D map of the colon, which
allows physicians to look for polyps and other abnormalities.
Designed to improve the patient experience and increase the
willingness of individuals to participate in recommended colorectal
cancer screening, C-Scan removes many frequently-cited barriers,
such as laxative bowel preparation, invasiveness and sedation.
Legal Notice Regarding Forward-Looking Statements
This press release contains "forward-looking statements." Words
such as "may," "should," "could," "would," "predicts," "potential,"
"continue," "expects," "anticipates," "future," "intends," "plans,"
"believes," "estimates," and similar expressions, as well as
statements in future tense, often signify forward-looking
statements. Forward-looking statements should not be read as a
guarantee of future performance or results and may not be accurate
indications of when such performance or results will be achieved.
Forward-looking statements are based on information that the
Company has when those statements are made or management's good
faith belief as of that time with respect to future events, and are
subject to risks and uncertainties that could cause actual
performance or results to differ materially from those expressed in
or suggested by the forward-looking statements. For a discussion of
these and other risks that could cause such differences and that
may affect the realization of forward-looking statements, please
refer to the "Special Note On Forward-looking Statements" and "Risk
Factors" in the Company's Annual Report on Form 20-F and other
filings with the Securities and Exchange Commission (SEC).
Investors and security holders are urged to read these documents
free of charge on the SEC's web site at http://www.sec.gov. The
Company assumes no obligation to publicly update or revise its
forward-looking statements as a result of new information, future
events or otherwise.
Investor Contacts
Vivian
Cervantes
PCG Advisory
646-863-6274
vivian@pcgadvisory.com
Meirav Gomeh-Bauer
+972-54-4764979
Meirav@bauerg.com
View original
content:http://www.prnewswire.com/news-releases/check-cap-receives-ce-mark-approval-for-c-scan-300580654.html
SOURCE Check-Cap Ltd.